We are live on
!
Find out more
1C
1623 Capital Portfolio holdings
AUM
$173M
1-Year Est. Return
17.08%
This Fund
S&P 500
This Quarter
Est. Return
+10.77%
1 Year Est. Return
+17.08%
3 Year Est. Return
+11.9%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$15.8M
(+6.4%)
Cap. Flow
-$7.5M
Cap. Flow
% of AUM
-2.88%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
96
New
12
Increased
33
Reduced
1
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Small-Cap ETF
IJR
|
+$1.49M |
| 2 |
Meta Platforms (Facebook)
META
|
+$962K |
| 3 |
Celsius Holdings
CELH
|
+$807K |
| 4 |
Airbnb
ABNB
|
+$784K |
| 5 |
PTC Therapeutics
PTCT
|
+$577K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$7.21M |
| 2 |
Zebra Technologies
ZBRA
|
+$2.57M |
| 3 |
PTC
PTC
|
+$438K |
| 4 |
NEWR
New Relic, Inc.
NEWR
|
+$320K |
| 5 |
Cloudflare
NET
|
+$289K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.59% |
| 2 | Healthcare | 12.91% |
| 3 | Consumer Discretionary | 12.59% |
| 4 | Financials | 11.76% |
| 5 | Communication Services | 10.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Teladoc Health
TDOC
$1.22B
| $506K | 0.19% |
3,041
+923
| +44% | +$150K |
|
|
ETWO
52
DELISTED
E2open Parent Holdings
ETWO
| $493K | 0.19% |
+43,176
| New | +$497K |
|
53
Kodiak Sciences
KOD
$2.6B
| $489K | 0.19% |
5,256
+3,314
| +171% | +$318K |
|
54
Penumbra
PEN
$12.7B
| $480K | 0.18% |
1,751
+393
| +29% | +$107K |
|
|
ZEN
55
DELISTED
ZENDESK INC
ZEN
| $459K | 0.18% |
3,183
+933
| +41% | +$132K |
|
56
TSMC
TSM
$2.1T
| $454K | 0.17% |
3,777
+2,926
| +344% | +$343K |
|
|
IS
57
DELISTED
ironSource Ltd.
IS
| $437K | 0.17% |
+41,658
| New | +$448K |
|
58
DexCom
DXCM
$31.5B
| $421K | 0.16% |
3,940
+1,652
| +72% | +$159K |
|
59
BioMarin Pharmaceuticals
BMRN
$11.6B
| $402K | 0.15% |
4,814
+2,962
| +160% | +$235K |
|
60
Marvell Technology
MRVL
$168B
| $371K | 0.14% |
+6,358
| New | +$311K |
|
61
Palantir
PLTR
$295B
| $361K | 0.14% |
13,691
+11,608
| +557% | +$268K |
|
62
Ultragenyx Pharmaceutical
RARE
$2.45B
| $360K | 0.14% |
3,777
+825
| +28% | +$86K |
|
63
Unity
U
$13.8B
| $352K | 0.14% |
3,203
+2,271
| +244% | +$223K |
|
|
NVTA
64
DELISTED
Invitae Corporation
NVTA
| $342K | 0.13% |
+10,135
| New | +$330K |
|
65
Roblox
RBLX
$25.4B
| $339K | 0.13% |
3,762
+2,490
| +196% | +$200K |
|
|
66
PUT
Teladoc Health
TDOC
$1.22B
| $333K | 0.13% |
+2,000
| New | +$324K |
|
67
Cognex
CGNX
$10.9B
| $332K | 0.13% |
+3,948
| New | +$319K |
|
|
NARI
68
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $328K | 0.13% |
+3,517
| New | +$341K |
|
69
Globus Medical
GMED
$10.7B
| $319K | 0.12% |
4,114
+1,390
| +51% | +$98.8K |
|
|
GTHX
70
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $207K | 0.08% |
9,432
+2,694
| +40% | +$59.8K |
|
71
PolyPid
PYPD
$82.3M
| $105K | 0.04% |
388
+87
| +29% | +$24.2K |
|
|
TECX
72
Tectonic Therapeutic
TECX
$529M
| $102K | 0.04% |
957
+451
| +89% | +$53.5K |
|
|
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-1,655
| Closed | -$71K |
|
74
CrowdStrike
CRWD
$194B
| – | – |
-1,020
| Closed | -$47K |
|
75
Precision BioSciences
DTIL
$180M
| – | – |
-409
| Closed | -$127K |
|
Similar funds
GA
CBC
WWP
IGWM
HWMA
RA
SWM
SVI
1623 Capital's Q2 2021 Portfolio in Review
As of Q2 2021, 1623 Capital held 96 positions worth $261M, up 6.4% from $245M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
1623 Capital's Q2 2021 filing shows 12 new, 33 increased, 1 reduced and 24 closed positions. Its largest new stake was Celsius Holdings: 39,618 shares worth $1M. The largest sale was Zscaler, an estimated $7.21M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- 1623 Capital's largest Q2 2021 buy was Celsius Holdings: 39,618 shares worth $1M.
- 1623 Capital added most to iShares Core S&P Small-Cap ETF in Q2 2021, an estimated $1.49M increase.
- 1623 Capital's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $17.7K.
- 1623 Capital fully exited Zscaler in Q2 2021, selling an estimated $7.21M.
- 1623 Capital's ten largest holdings make up 43% of its $261M portfolio in Q2 2021.
- 1623 Capital opened 12 new positions and closed 24 in Q2 2021.
- 1623 Capital's portfolio value rose 6.4% quarter-over-quarter to $261M.
Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.